(NASDAQ: MNOV) Medicinova's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.93%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.08%.
Medicinova's earnings in 2026 is -$11,997,957.On average, 4 Wall Street analysts forecast MNOV's earnings for 2026 to be -$16,065,815, with the lowest MNOV earnings forecast at -$18,329,992, and the highest MNOV earnings forecast at -$13,437,400. On average, 3 Wall Street analysts forecast MNOV's earnings for 2027 to be -$20,082,268, with the lowest MNOV earnings forecast at -$19,294,728, and the highest MNOV earnings forecast at -$20,672,923.
In 2028, MNOV is forecast to generate -$22,090,495 in earnings, with the lowest earnings forecast at -$21,224,201 and the highest earnings forecast at -$22,740,216.